QURE

uniQure N.V. (QURE) | Rumor.io

uniQure

QURE

Attention (50-day avg)0.01%

Attention rank (50-day avg)#418

Bullish sentiment (50-day avg)72%

Price to earnings ratio-11.3

Market capitalization2.7B

Earnings per share-4.06

Dividend yield (TTM)—

Revenue (annual)16.1M

Net income (annual)-199M

Social

What share of all stock conversation is about QURE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.01	0.02% +0	0.01% +0	0.01% +0

Sep 29

uniQure's AMT-130 gene therapy for Huntington's disease showed a 44% slowing of progression at 48 months, down from 80% at 36 months, with the 4-year data not being statistically significant.
The FDA's approval case for AMT-130 was based on the 36-month data, and the new 48-month data may not be enough to change the agency's decision.
Despite the setback, many experts believe that uniQure's therapy will still be approved, as it has shown a substantial disease-modifying effect and is a significant step forward in treating Huntington's disease.

Generated by AI

Sentiment

Of the messages about QURE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	55.22% -44.78	50.32% -20.94	69.06% -10.92	56.08% -28.37
Bearish	44.78% +44.78	49.68% +20.94	30.94% +10.92	43.92% +28.37

Bullish· Sep 29

UniQure N.V. ($QURE) has a high potential for recovery, with some predicting a rebound to $50+.
The FDA's new approach may lead to approval, especially with strong disease-modifying evidence and significant advancements in the field, as seen in the AMT-130 data.
Despite a temporary dip, $QURE is expected to settle back into the high 20s to near 30s, with long-term bullish prospects and potential acceptance from the FDA.

Bearish· Sep 29

The stock has experienced significant losses, with some posts mentioning specific percentages, such as a 54% drop in pre-market or a 72% decline.
The company's data has been deemed "failing" or "uninteresting", with one post stating that the stock is "dead" and bounces are "irrelevant".
The stock's price has been affected by a large sell-off, with one post mentioning that a "whale" (a large investor) dumped a short position, and another post stating that some people have been burned by holding the stock.

Generated by AI

Topics

Of the messages about QURE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0.45%	11.55%	62.89%	19.05%
Technical Analysis	35.87%	31.87%	11.43%	1.19%
Macro	31.84%	28.29%	10.31%	35.24%
Earnings	0%	0%	1.12%	4.98%
Analysts	31.84%	28.29%	14.13%	36.09%
Controversies	0%	0%	0.11%	3.45%

Earnings· Mar 14

uniQure N.V. (QURE) missed EPS estimates by 29 cents.
QURE beat revenue estimates by $0.37 million.
QURE reported FQ4 earnings of -91 cents EPS and $2.58 million in revenues.

Analysts· Mar 9

Wells Fargo upgraded uniQure to Overweight from Equal Weight with a price target of $60, up from $15, citing an improved outlook for the company's AMT-130 in Huntington's disease treatment.
RBC Capital upgraded uniQure to Outperform from Sector Perform, raising the price target to $35 from $11, and assigning a 50% probability of eventual approval for the Huntington's disease treatment.
The upgrades were driven by the expected departure of Vinay Prasad from the FDA, which is seen as improving the regulatory outlook for gene therapy companies, including uniQure.

Announcements· Jun 22

uniQure announced preliminary data from the first cohort of its Phase I/IIa clinical trial of AMT-260 in refractory mesial temporal lobe epilepsy, with AMT-260 being generally well tolerated with no serious adverse events observed.
Stifel notes that the findings represent a promising start for uniQure and AMT-260, with potential for better efficacy in the high-dose cohort.
uniQure is launching a $150M ordinary-share and pre-funded warrant offering to support AMT-130 launch readiness and a confirmatory study, with proceeds earmarked for these purposes.

Controversies· Nov 3

The FDA has reversed its stance on uniQure's (QURE) Huntington's disease gene therapy, AMT-130, stating that the current Phase I/II data is not sufficient for a Biologics License Application (BLA) submission.
The FDA's change in stance has caused a significant regulatory setback for QURE, with the company planning to pursue new accelerated approval paths in the US, EU, and UK.
The controversy surrounding QURE's AMT-130 has led to a 66% plunge in the company's stock, with some questioning whether the FDA's actions are justified and whether the company should be sued.

Technical Analysis· Sep 24

uniQure N.V. ($QURE) has a potential double top formation on the five-year chart, with a previous spike to $51 followed by a sell-off to $30.
Technical analysis suggests $QURE may be overbought, with a rising wedge in the daily chart and a potential dip to the 200-day EMA.
The stock has been identified as a potential short opportunity, with a 50% retrace target at $28 and a possible gap down to $20.

Generated by AI

Community

Of the messages about QURE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	64.76%	86.23%	85.62%	60.58%
Newcomers	35.24%	13.77%	14.38%	39.42%

Regulars· Sep 29

The 48-month data for uniQure's AMT-130 may not change the FDA's review of the drug, as the agency had already agreed that the 36-month analysis could be the primary basis of the accelerated-approval BLA.
The long-term efficacy of AMT-130 has been questioned, with some investors citing concerns over the drug's ability to slow disease progression in patients with Huntington's disease.
The data from uniQure's 48-month trial may be seen as additional supportive evidence for the drug's approval, rather than a replacement for the dataset used in the filing, which was based on 36-month results.

Newcomers· Sep 29

The new 4-year data from uniQure's AMT-130 gene therapy trial for Huntington's disease shows a slower progression of the disease, but the result lost statistical significance compared to the 3-year data.
The FDA review of uniQure's BLA (biologics license application) is ongoing, and the 4-year data may be seen as a durability issue rather than a reason to reject the application.
Some investors believe that the stock will recover and get approved via an adcom (advisory committee) review, while others think the data is a reason to short the stock and predict a price drop to $5.

Generated by AI

News

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

11h agoMorningstar

UniQure plunges as Huntington's trial data disappoints investors

14h agoReuters

uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit

16h agoYahoo Finance

uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE)

uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.

17h agoSeeking Alpha

uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing - Slideshow (NASDAQ:QURE) 2026-09-29

18h agoSeeking Alpha

Why Is uniQure Stock Sinking on Tuesday?

uniQure N.V. (NASDAQ:QURE) stock is trading lower on Tuesday after the company shared mixed long-term data from ongoing Phase 1/2 clinical studies evaluating ifezuntirgene inilparvovec for Huntington’s disease. 36-Month Clinical Results And BLA Pathway In the 36-month analysis, high-dose patients demonstrated an 80% slowing of disease progression on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) and a 67% slowing on Total Functional Capacity (TFC). cUHDRS is a specialized scori

22h agoYahoo Finance

Also Discussed

Investors talking about QURE also mention

#	Name	Attention
1	Regenxbio Inc.RGNX	0%+0
2	ClearPoint Neuro Inc.CLPT	0.03%+0.02
3	Abivax SAABVX	0.01%-0.01
4	Biohaven Ltd.BHVN	0%-0.01
5	SGMO - Sangamo Therapeutics, Inc.	——
6	Nektar TherapeuticsNKTR	0.08%+0.03
7	BioMarin Pharmaceutical IncBMRN	0%+0
8	Sarepta Therapeutics, Inc.SRPT	0%-0.01
9	Wave Life Sciences Ltd.WVE	0%+0
10	Replimune Group, Inc.REPL	0%0

uniQure N.V.

Healthcare
Biotechnology

uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.

Website

Location

Paasheuvelweg 25

Amsterdam, 1105 BP

Netherlands

Social

What share of all stock conversation is about QURE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.01	0.02% +0	0.01% +0	0.01% +0

Sep 29

uniQure's AMT-130 gene therapy for Huntington's disease showed a 44% slowing of progression at 48 months, down from 80% at 36 months, with the 4-year data not being statistically significant.
The FDA's approval case for AMT-130 was based on the 36-month data, and the new 48-month data may not be enough to change the agency's decision.
Despite the setback, many experts believe that uniQure's therapy will still be approved, as it has shown a substantial disease-modifying effect and is a significant step forward in treating Huntington's disease.

Generated by AI

Sentiment

Of the messages about QURE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	55.22% -44.78	50.32% -20.94	69.06% -10.92	56.08% -28.37
Bearish	44.78% +44.78	49.68% +20.94	30.94% +10.92	43.92% +28.37

Bullish· Sep 29

UniQure N.V. ($QURE) has a high potential for recovery, with some predicting a rebound to $50+.
The FDA's new approach may lead to approval, especially with strong disease-modifying evidence and significant advancements in the field, as seen in the AMT-130 data.
Despite a temporary dip, $QURE is expected to settle back into the high 20s to near 30s, with long-term bullish prospects and potential acceptance from the FDA.

Bearish· Sep 29

The stock has experienced significant losses, with some posts mentioning specific percentages, such as a 54% drop in pre-market or a 72% decline.
The company's data has been deemed "failing" or "uninteresting", with one post stating that the stock is "dead" and bounces are "irrelevant".
The stock's price has been affected by a large sell-off, with one post mentioning that a "whale" (a large investor) dumped a short position, and another post stating that some people have been burned by holding the stock.

Generated by AI

Topics

Of the messages about QURE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0.45%	11.55%	62.89%	19.05%
Technical Analysis	35.87%	31.87%	11.43%	1.19%
Macro	31.84%	28.29%	10.31%	35.24%
Earnings	0%	0%	1.12%	4.98%
Analysts	31.84%	28.29%	14.13%	36.09%
Controversies	0%	0%	0.11%	3.45%

Earnings· Mar 14

uniQure N.V. (QURE) missed EPS estimates by 29 cents.
QURE beat revenue estimates by $0.37 million.
QURE reported FQ4 earnings of -91 cents EPS and $2.58 million in revenues.

Analysts· Mar 9

Wells Fargo upgraded uniQure to Overweight from Equal Weight with a price target of $60, up from $15, citing an improved outlook for the company's AMT-130 in Huntington's disease treatment.
RBC Capital upgraded uniQure to Outperform from Sector Perform, raising the price target to $35 from $11, and assigning a 50% probability of eventual approval for the Huntington's disease treatment.
The upgrades were driven by the expected departure of Vinay Prasad from the FDA, which is seen as improving the regulatory outlook for gene therapy companies, including uniQure.

Announcements· Jun 22

uniQure announced preliminary data from the first cohort of its Phase I/IIa clinical trial of AMT-260 in refractory mesial temporal lobe epilepsy, with AMT-260 being generally well tolerated with no serious adverse events observed.
Stifel notes that the findings represent a promising start for uniQure and AMT-260, with potential for better efficacy in the high-dose cohort.
uniQure is launching a $150M ordinary-share and pre-funded warrant offering to support AMT-130 launch readiness and a confirmatory study, with proceeds earmarked for these purposes.

Controversies· Nov 3

The FDA has reversed its stance on uniQure's (QURE) Huntington's disease gene therapy, AMT-130, stating that the current Phase I/II data is not sufficient for a Biologics License Application (BLA) submission.
The FDA's change in stance has caused a significant regulatory setback for QURE, with the company planning to pursue new accelerated approval paths in the US, EU, and UK.
The controversy surrounding QURE's AMT-130 has led to a 66% plunge in the company's stock, with some questioning whether the FDA's actions are justified and whether the company should be sued.

Technical Analysis· Sep 24

uniQure N.V. ($QURE) has a potential double top formation on the five-year chart, with a previous spike to $51 followed by a sell-off to $30.
Technical analysis suggests $QURE may be overbought, with a rising wedge in the daily chart and a potential dip to the 200-day EMA.
The stock has been identified as a potential short opportunity, with a 50% retrace target at $28 and a possible gap down to $20.

Generated by AI

Community

Of the messages about QURE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	64.76%	86.23%	85.62%	60.58%
Newcomers	35.24%	13.77%	14.38%	39.42%

Regulars· Sep 29

The 48-month data for uniQure's AMT-130 may not change the FDA's review of the drug, as the agency had already agreed that the 36-month analysis could be the primary basis of the accelerated-approval BLA.
The long-term efficacy of AMT-130 has been questioned, with some investors citing concerns over the drug's ability to slow disease progression in patients with Huntington's disease.
The data from uniQure's 48-month trial may be seen as additional supportive evidence for the drug's approval, rather than a replacement for the dataset used in the filing, which was based on 36-month results.

Newcomers· Sep 29

The new 4-year data from uniQure's AMT-130 gene therapy trial for Huntington's disease shows a slower progression of the disease, but the result lost statistical significance compared to the 3-year data.
The FDA review of uniQure's BLA (biologics license application) is ongoing, and the 4-year data may be seen as a durability issue rather than a reason to reject the application.
Some investors believe that the stock will recover and get approved via an adcom (advisory committee) review, while others think the data is a reason to short the stock and predict a price drop to $5.

Generated by AI

uniQure

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Mar 14

Analysts· Mar 9

Announcements· Jun 22

Controversies· Nov 3

Technical Analysis· Sep 24

Regulars· Sep 29

Newcomers· Sep 29

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

UniQure plunges as Huntington's trial data disappoints investors

uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit

uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE)

uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing - Slideshow (NASDAQ:QURE) 2026-09-29

Why Is uniQure Stock Sinking on Tuesday?

Also Discussed

uniQure N.V.

Company Information

Location

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

UniQure plunges as Huntington's trial data disappoints investors

uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit

uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE)

uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing - Slideshow (NASDAQ:QURE) 2026-09-29

Why Is uniQure Stock Sinking on Tuesday?

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Mar 14

Analysts· Mar 9

Announcements· Jun 22

Controversies· Nov 3

Technical Analysis· Sep 24

Regulars· Sep 29

Newcomers· Sep 29